



| Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body´s immune response |
| • | FDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in critically ill invasively mechanically ventilated COVID-19 patients |
| • | InflaRx continues the dialogue with FDA to discuss next steps towards a Biologics License Application submission for full approval |
| • | Encouraging pre-submission meetings held with EMA in Europe; InflaRx plans to apply for full approval to treat critically ill COVID-19 patients |
| • | Company to host a conference call tomorrow, April 5th at 8:30 am EDT/2:30 pm CEST |


